Adma Biologics Inc (NASDAQ: ADMA) closed the day trading at $6.22 up 0.65% from the previous closing price of $6.18. In other words, the price has increased by $+0.04 from its previous closing price. On the day, 2496805 shares were traded. ADMA stock price reached its highest trading level at $6.36 during the session, while it also had its lowest trading level at $6.12.
Ratios:
For a better understanding of ADMA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 27.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 352.24. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 1.04.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 30 ’23 when Grossman Jerrold B bought 130,000 shares for $3.71 per share. The transaction valued at 482,144 led to the insider holds 443,265 shares of the business.
KWON YOUNG bought 25,000 shares of ADMA for $97,500 on Aug 24 ’23. The Director now owns 277,401 shares after completing the transaction at $3.90 per share. On Aug 22 ’23, another insider, Fong Bryant, who serves as the Director of the company, sold 1,433,304 shares for $3.87 each. As a result, the insider received 5,544,737 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 1.42B and an Enterprise Value of 1.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.50 while its Price-to-Book (P/B) ratio in mrq is 10.40. Its current Enterprise Value per Revenue stands at 5.85 whereas that against EBITDA is 294.84.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $6.41, while it has fallen to a 52-week low of $2.94. The 50-Day Moving Average of the stock is 5.25, while the 200-Day Moving Average is calculated to be 4.16.
Shares Statistics:
Over the past 3-months, ADMA traded about 2.63M shares per day on average, while over the past 10 days, ADMA traded about 4.14M shares per day. A total of 226.06M shares are outstanding, with a floating share count of 218.15M. Insiders hold about 4.41% of the company’s shares, while institutions hold 74.30% stake in the company. Shares short for ADMA as of Feb 29, 2024 were 6.72M with a Short Ratio of 2.56, compared to 6.84M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.95% and a Short% of Float of 3.09%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.32 and $0.28 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.5, with 4 analysts recommending between $0.51 and $0.48.
Revenue Estimates
4 analysts predict $77.27M in revenue for the current quarter. It ranges from a high estimate of $79.7M to a low estimate of $76M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $56.91M, an estimated increase of 35.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $81.27M, an increase of 35.20% less than the figure of $35.80% in the same quarter last year. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $78.4M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $337M, while the lowest revenue estimate was $331.9M, resulting in an average revenue estimate of $333.87M. In the same quarter a year ago, actual revenue was $258.21M, up 29.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $389.87M in the next fiscal year. The high estimate is $395.5M and the low estimate is $383.5M. The average revenue growth estimate for next year is up 16.80% from the average revenue estimate for this year.
